Physician profile
Jason Alan Smith
NPI 1861604241
$8,171.95
in general payments reported to CMS, 2019-2025
42 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,211 · 2020: $402 · 2021: $674 · 2022: $675 · 2023: $612 · 2024: $853 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $3,626.35 | 2019-2024 | Xtandi, Veozah, Myrbetriq |
| Janssen Biotech, INC. | $728.55 | 2019-2025 | Erleada, Akeega |
| 180 Medical, INC. | $550.70 | 2020-2025 | Gentlecath, Self-Cath, Gentlecath Glide |
| Bayer Healthcare Pharmaceuticals INC. | $484.72 | 2019-2025 | |
| Abbvie INC. | $310.24 | 2022-2025 | Botox |
| Endo Pharmaceuticals INC. | $269.21 | 2019-2024 | Xiaflex, Aveed |
| Neotract INC. | $238.11 | 2019 | |
| Olympus America INC. | $200.28 | 2021-2024 | Itind System |
| Dendreon Pharmaceuticals LLC | $191.41 | 2019-2024 | Provenge |
| Medtronic USA, INC. | $167.30 | 2019 | |
| Allergan, INC. | $165.15 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $147.27 | 2023-2025 | Gemtesa |
| Immunitybio, INC. | $135.17 | 2025 | |
| Teleflex LLC | $113.24 | 2022 | |
| Coloplast Corp | $96.66 | 2023-2024 | Porges Coloplast |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.